| Sarah Lauridson, SLP | |
|
317 Martin Luther King Jr Way, Tacoma, WA 98405-4234 | |
| (253) 403-1400 | |
| Not Available |
| Full Name | Sarah Lauridson |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 317 Martin Luther King Jr Way, Tacoma, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821794603 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 61357583 (Washington) | Primary |
| Provider Name | Multicare Health System |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
Mr. Chairman and Ranking Member, on behalf of the American Association for Homecare's more than 4,000 member locations serving Medicare beneficiaries in every state in the nation, we appreciate the opportunity to submit this statement to the Senate Committee on the Judiciary regarding the need to eliminate waste and fraud in Medicare and Medicaid.
Anthem Blue Cross and Blue Shield in Maine has announced that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.
TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.
Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.
An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers reported their results at the 2006 ASM Biodefense Research Meeting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Lauridson, SLP 7106 71st Ave Nw, Gig Harbor, WA 98335-6303 Ph: (916) 835-8315 | Sarah Lauridson, SLP 317 Martin Luther King Jr Way, Tacoma, WA 98405-4234 Ph: (253) 403-1400 |
News Archive
Mr. Chairman and Ranking Member, on behalf of the American Association for Homecare's more than 4,000 member locations serving Medicare beneficiaries in every state in the nation, we appreciate the opportunity to submit this statement to the Senate Committee on the Judiciary regarding the need to eliminate waste and fraud in Medicare and Medicaid.
Anthem Blue Cross and Blue Shield in Maine has announced that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.
TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.
Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.
An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers reported their results at the 2006 ASM Biodefense Research Meeting.
› Verified 6 days ago
Andrea Lynn Rottier, LL Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4301 S Pine St, Ste 219, Tacoma, WA 98409 Phone: 253-476-6550 | |
Janet Kobayashi-hobson, CCC Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 315 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-403-1000 | |
Christine L Camp, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2106 E 44th St, Tacoma, WA 98404 Phone: 253-571-2908 | |
Ann S Lewis, B.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1202 S 76th St, Tacoma, WA 98408 Phone: 253-571-4579 | |
Angela Curtis, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-7919 | |
Porsche Maneice, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 242 St Helens Ave, Tacoma, WA 98402 Phone: 253-627-3833 | |
Peggy Lesniak, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1310 S Union Ave Ste A100, Tacoma, WA 98405 Phone: 253-383-2423 |